2021615

Congress Keiichi Fukuda, CEO gave a presentation titled "Clinical Application of Human iPS Cell-Derived Ventricular Cardiomyocytes for Heart Failure Treatment" at Deep Tech in Asia: Stem Cell Innovations by SGInnovate.

2021611

PR Heartseed raises $37 million in Series C Funding

2021611

Other Tatsuyoshi Hirano was appointed as Chief Administrative Officer

202161

PR Heartseed and Novo Nordisk enter into global collaboration and licence agreement for stem cell-based therapy for heart failure

2021510

Media An interview with Kikuo Yasui, COO, was published in the Japan Times.

2021421

Media Heartseed was featured as a cover story in Startup City Magazine's "Top 10 Startups in Japan"

2021323

PR Heartseed Initiates Ph1/2 Clinical Trial of iPSC-derived Cardiomyocyte Spheroids (LAPiS Study) in Japan

202131

PR Heartseed named "Minister of Science and Technology Policy Award"  at Japan Venture Awards 2021

2021128

Other Taiji Edogawa was appointed as External Audit & Supervisory Board Member

20201130

PR Heartseed Named "Healthcare Company of the Year 2020" by Healthcare Insights Magazine